Literature DB >> 26136984

Analgesic roles of peripheral intrinsic met-enkephalin and dynorphin A in long-lasting inflammatory pain induced by complete Freund's adjuvant in rats.

Yong-Liang Jiang1, Xiao-Fen He1, Ya-Fang Shen1, Xiao-Hu Yin1, Jun-Ying DU1, Y I Liang1, Jian-Qiao Fang1.   

Abstract

Previous studies have focused on strategies for pain relief based on the peripheral opioid system. However, little is known with regard to the profile of the peripheral opioid system in long-lasting inflammatory pain. In the current study, the intrinsic changes of the peripheral opioids were investigated in long-lasting inflammatory pain. A rat model of complete Freund's adjuvant (CFA)-induced inflammatory pain was established. Paw swelling and thermal hyperalgesia (paw withdrawal latency, PWL) were analyzed until day 18 after the CFA injection. The levels of peripheral opioids and their upstream inducers, corticotrophin-releasing factor (CRF) and interleukin (IL)-1β, were measured, and validation experiments were performed using opioid receptor antagonists. Long-lasting inflammatory pain was successfully induced in the rats, as shown by the significantly increased paw swelling and decreased PWLs. On day 18 after the CFA injection, the IL-1β levels were significantly elevated, while CRF remained at a normal level in the paw inflammatory tissue. In addition, met-enkephalin (Met-ENK) and dynorphin A (DYN A) levels were significantly increased, while the β-endorphin level remained normal. Local intraplantar administration of δ- and κ-opioid receptor antagonists resulted in more substantial pain, but did not significantly affect the PWLs of the normal control rats. Therefore, the results indicated that the increased levels of local Met-ENK and DYN A in CFA-induced long-lasting inflammatory pain may be involved in peripheral intrinsic analgesia.

Entities:  

Keywords:  analgesia; complete Freund's adjuvant; inflammatory pain; peripheral opioid

Year:  2015        PMID: 26136984      PMCID: PMC4473374          DOI: 10.3892/etm.2015.2407

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  19 in total

Review 1.  No pain, no gain: clinical excellence and scientific rigour--lessons learned from IA morphine.

Authors:  Eija Kalso; Lesley Smith; Henry J McQuay; Andrew R Moore
Journal:  Pain       Date:  2002-08       Impact factor: 6.961

Review 2.  Leukocytes in the regulation of pain and analgesia.

Authors:  H L Rittner; H Machelska; C Stein
Journal:  J Leukoc Biol       Date:  2005-10-04       Impact factor: 4.962

3.  Protective effects of indomethacin and cyclophosphamide but not of infliximab on liver metabolic changes caused by adjuvant-induced arthritis.

Authors:  Maria Angélica Raffaini Covas Pereira da Silva; Ciomar Aparecida Bersani-Amado; Emy Luiza Ishii-Iwamoto; Lívia Bracht; Silvana Martins Caparroz-Assef
Journal:  Inflammation       Date:  2011-12       Impact factor: 4.092

Review 4.  Peripheral opioid receptors.

Authors:  C Stein; M Schäfer; A H Hassan
Journal:  Ann Med       Date:  1995-04       Impact factor: 4.709

5.  Interleukin-1 beta contributes to the upregulation of kappa opioid receptor mrna in dorsal root ganglia in response to peripheral inflammation.

Authors:  W Puehler; H L Rittner; S A Mousa; A Brack; H Krause; C Stein; M Schäfer
Journal:  Neuroscience       Date:  2006-06-19       Impact factor: 3.590

6.  Opioid peptide-expressing leukocytes: identification, recruitment, and simultaneously increasing inhibition of inflammatory pain.

Authors:  H L Rittner; A Brack; H Machelska; S A Mousa; M Bauer; M Schäfer; C Stein
Journal:  Anesthesiology       Date:  2001-08       Impact factor: 7.892

Review 7.  Peripherally acting opioids and clinical implications for pain control.

Authors:  Nalini Sehgal; Howard S Smith; Laxmaiah Manchikanti
Journal:  Pain Physician       Date:  2011 May-Jun       Impact factor: 4.965

8.  Sympathetic activation triggers endogenous opioid release and analgesia within peripheral inflamed tissue.

Authors:  Waltraud Binder; Shaaban A Mousa; Nicolle Sitte; Myriam Kaiser; Christoph Stein; Michael Schäfer
Journal:  Eur J Neurosci       Date:  2004-07       Impact factor: 3.386

9.  Involvement of corticotropin-releasing hormone receptor subtypes 1 and 2 in peripheral opioid-mediated inhibition of inflammatory pain.

Authors:  Shaaban A Mousa; P C Bopaiah; Christoph Stein; Michael Schäfer
Journal:  Pain       Date:  2003-12       Impact factor: 6.961

10.  Different mechanisms of intrinsic pain inhibition in early and late inflammation.

Authors:  Halina Machelska; Julia K Schopohl; Shaaban A Mousa; Dominika Labuz; Michael Schäfer; Christoph Stein
Journal:  J Neuroimmunol       Date:  2003-08       Impact factor: 3.478

View more
  10 in total

1.  Effects of electroacupuncture at 2 and 100 Hz on rat type 2 diabetic neuropathic pain and hyperalgesia-related protein expression in the dorsal root ganglion.

Authors:  Xiao-Fen He; Jun-Jun Wei; Sheng-Yun Shou; Jian-Qiao Fang; Yong-Liang Jiang
Journal:  J Zhejiang Univ Sci B       Date:  2017 Mar.       Impact factor: 3.066

2.  Dual-Acting Peripherally Restricted Delta/Kappa Opioid (CAV1001) Produces Antinociception in Animal Models of Sub-Acute and Chronic Pain.

Authors:  Craig T Hartrick; Dominic Poulin; Rebekka Molenaar; Allison Hartrick
Journal:  J Pain Res       Date:  2020-10-06       Impact factor: 3.133

3.  Positive allosteric modulation of the mu-opioid receptor produces analgesia with reduced side effects.

Authors:  Ram Kandasamy; Todd M Hillhouse; Kathryn E Livingston; Kelsey E Kochan; Claire Meurice; Shainnel O Eans; Ming-Hua Li; Andrew D White; Bernard P Roques; Jay P McLaughlin; Susan L Ingram; Neil T Burford; Andrew Alt; John R Traynor
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-20       Impact factor: 11.205

4.  Chitosan Oligosaccharide Reduces Propofol Requirements and Propofol-Related Side Effects.

Authors:  Zhiwen Li; Xige Yang; Xuesong Song; Haichun Ma; Ping Zhang
Journal:  Mar Drugs       Date:  2016-12-21       Impact factor: 5.118

5.  Analgesic Effect of Moxibustion with Different Temperature on Inflammatory and Neuropathic Pain Mice: A Comparative Study.

Authors:  Wei Zhou; Ruxue Lei; Chuanyi Zuo; Yunqing Yue; Qin Luo; Chengshun Zhang; Peng Lv; Yong Tang; Haiyan Yin; Shuguang Yu
Journal:  Evid Based Complement Alternat Med       Date:  2017-10-09       Impact factor: 2.629

Review 6.  Modulation of the Negative Affective Dimension of Pain: Focus on Selected Neuropeptidergic System Contributions.

Authors:  Francesca Felicia Caputi; Laura Rullo; Serena Stamatakos; Sanzio Candeletti; Patrizia Romualdi
Journal:  Int J Mol Sci       Date:  2019-08-17       Impact factor: 5.923

7.  Inflammatory and healing environment in synovial fluid after anterior cruciate ligament reconstruction: Granulocytes and endogenous opioids as new targets of postoperative pain.

Authors:  Hiroki Katagiri; Kaori Nakamura; Takeshi Muneta; Toshifumi Watanabe; Kazumasa Miyatake; Ichiro Sekiya; Hideyuki Koga; Kunikazu Tsuji
Journal:  Biochem Biophys Rep       Date:  2021-04-25

8.  Effect of Moxibustion on β-EP and Dyn Levels of Pain-Related Indicators in Patients with Rheumatoid Arthritis.

Authors:  Yingni Wang; Siyu Tao; Zeyun Yu; Yun Luo; Yuan Li; Jie Tang; Guanhua Chen; Rouxian Shuai; Xinyue Hu; Ping Wu
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-03       Impact factor: 2.629

Review 9.  Opioids and Ocular Surface Pathology: A Literature Review of New Treatments Horizons.

Authors:  Celia García-López; Carmen Gómez-Huertas; José-María Sánchez-González; Davide Borroni; Marina Rodríguez-Calvo-de-Mora; Vito Romano; Rahul Rachwani-Anil; Juan-Francisco Ramos-López; Santiago Ortiz-Pérez; Carlos Rocha-de-Lossada
Journal:  J Clin Med       Date:  2022-03-04       Impact factor: 4.241

10.  The α5 subunit containing GABAA receptors contribute to chronic pain.

Authors:  Mariana Bravo-Hernández; José A Corleto; Paulino Barragán-Iglesias; Ricardo González-Ramírez; Jorge B Pineda-Farias; Ricardo Felix; Nigel A Calcutt; Rodolfo Delgado-Lezama; Martin Marsala; Vinicio Granados-Soto
Journal:  Pain       Date:  2016-03       Impact factor: 7.926

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.